STOCK TITAN

[Form 4] AtriCure, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sven Wehrwein, a director of AtriCure, Inc. (ATRC), executed matched transactions on 08/22/2025. He exercised 5,000 non-qualified stock options with an exercise price of $19.95, acquiring 5,000 shares. He simultaneously sold 5,000 common shares at $37.00. After these transactions he beneficially owned 34,374 shares and held options covering 35,000 shares exercisable through 11/11/2026. The options were originally granted on November 11, 2016, and vest per the schedule disclosed in the filing.

Sven Wehrwein, dirigente di AtriCure, Inc. (ATRC), ha effettuato operazioni abbinate il 22/08/2025. Ha esercitato 5.000 opzioni su azioni non qualificate con prezzo di esercizio di $19,95, acquisendo 5.000 azioni. Contemporaneamente ha venduto 5.000 azioni ordinarie a $37,00 ciascuna. Dopo queste operazioni deteneva la titolarità effettiva di 34.374 azioni e possedeva opzioni su 35.000 azioni esercitabili fino al 11/11/2026. Le opzioni erano state originate il 11 novembre 2016 e maturano secondo il piano indicato nel documento.

Sven Wehrwein, director de AtriCure, Inc. (ATRC), realizó operaciones compensadas el 22/08/2025. Ejerció 5.000 opciones sobre acciones no calificadas con un precio de ejercicio de $19,95, adquiriendo 5.000 acciones. Simultáneamente vendió 5.000 acciones ordinarias a $37,00 cada una. Tras estas transacciones poseía beneficiosamente 34.374 acciones y tenía opciones sobre 35.000 acciones ejercitables hasta el 11/11/2026. Las opciones se otorgaron originalmente el 11 de noviembre de 2016 y vencen según el calendario divulgado en el expediente.

AtriCure, Inc.(ATRC) 이사인 Sven Wehrwein은 2025년 8월 22일에 매치드 거래를 실행했습니다. 그는 행사가격 $19.95인 비적격 스톡옵션 5,000주를 행사하여 5,000주를 취득했습니다. 동시에 보통주 5,000주를 주당 $37.00에 매도했습니다. 이 거래 후 그는 실질적으로 34,374주를 보유하게 되었고, 2026년 11월 11일까지 행사 가능한 35,000주 분의 옵션을 보유하고 있었습니다. 해당 옵션은 2016년 11월 11일에 부여되었으며, 공시된 일정에 따라 베스팅됩니다.

Sven Wehrwein, administrateur d’AtriCure, Inc. (ATRC), a réalisé des opérations appariées le 22/08/2025. Il a levé 5 000 options d’achat non qualifiées au prix d’exercice de 19,95 $, acquérant ainsi 5 000 actions. Simultanément, il a vendu 5 000 actions ordinaires à 37,00 $ chacune. Après ces opérations, il détenait de manière bénéficiaire 34 374 actions et disposait d’options couvrant 35 000 actions exerçables jusqu’au 11/11/2026. Les options avaient été initialement attribuées le 11 novembre 2016 et acquièrent des droits selon le calendrier indiqué dans le dossier.

Sven Wehrwein, Direktor von AtriCure, Inc. (ATRC), führte am 22.08.2025 abgeglichene Transaktionen durch. Er übte 5.000 nicht qualifizierte Aktienoptionen zum Ausübungspreis von $19,95 aus und erwarb 5.000 Aktien. Gleichzeitig verkaufte er 5.000 Stammaktien zu $37,00 pro Aktie. Nach diesen Transaktionen hielt er wirtschaftlich 34.374 Aktien und verfügte über Optionen auf 35.000 Aktien, die bis zum 11.11.2026 ausübbar sind. Die Optionen wurden ursprünglich am 11. November 2016 gewährt und vesten gemäß dem im Bericht angegebenen Zeitplan.

Positive
  • Timely disclosure of the director's transactions consistent with Section 16 reporting requirements
  • Exercise retained substantial exposure: after the transactions the reporting person still beneficially owns 34,374 shares and holds options on 35,000 shares exercisable through 11/11/2026
Negative
  • Same-day sale of shares (5,000 sold at $37.00) may indicate partial liquidity-taking rather than additional long-term accumulation
  • Potential dilution from outstanding options (35,000 exercisable) which could increase share count if exercised

Insights

TL;DR: Director exercised options and sold an equal number of shares same day, leaving substantial remaining option holdings.

The filing shows a routine option exercise and sale: 5,000 options exercised at $19.95 and 5,000 shares sold at $37.00 on 08/22/2025. The director retains meaningful exposure via 34,374 beneficially owned shares and 35,000 exercisable options. This pattern often reflects liquidity-taking after exercise rather than a fundamental change in conviction.

TL;DR: Transaction pattern is consistent with planned exercise-and-sell activity by insiders, disclosed under Section 16 reporting.

The Form 4 discloses timely reporting of matched transactions and confirms option grant and vesting schedule from 2016. No evidence in the filing of unusual trading, derivative restructuring, or new agreements; disclosures appear complete for these transactions.

Sven Wehrwein, dirigente di AtriCure, Inc. (ATRC), ha effettuato operazioni abbinate il 22/08/2025. Ha esercitato 5.000 opzioni su azioni non qualificate con prezzo di esercizio di $19,95, acquisendo 5.000 azioni. Contemporaneamente ha venduto 5.000 azioni ordinarie a $37,00 ciascuna. Dopo queste operazioni deteneva la titolarità effettiva di 34.374 azioni e possedeva opzioni su 35.000 azioni esercitabili fino al 11/11/2026. Le opzioni erano state originate il 11 novembre 2016 e maturano secondo il piano indicato nel documento.

Sven Wehrwein, director de AtriCure, Inc. (ATRC), realizó operaciones compensadas el 22/08/2025. Ejerció 5.000 opciones sobre acciones no calificadas con un precio de ejercicio de $19,95, adquiriendo 5.000 acciones. Simultáneamente vendió 5.000 acciones ordinarias a $37,00 cada una. Tras estas transacciones poseía beneficiosamente 34.374 acciones y tenía opciones sobre 35.000 acciones ejercitables hasta el 11/11/2026. Las opciones se otorgaron originalmente el 11 de noviembre de 2016 y vencen según el calendario divulgado en el expediente.

AtriCure, Inc.(ATRC) 이사인 Sven Wehrwein은 2025년 8월 22일에 매치드 거래를 실행했습니다. 그는 행사가격 $19.95인 비적격 스톡옵션 5,000주를 행사하여 5,000주를 취득했습니다. 동시에 보통주 5,000주를 주당 $37.00에 매도했습니다. 이 거래 후 그는 실질적으로 34,374주를 보유하게 되었고, 2026년 11월 11일까지 행사 가능한 35,000주 분의 옵션을 보유하고 있었습니다. 해당 옵션은 2016년 11월 11일에 부여되었으며, 공시된 일정에 따라 베스팅됩니다.

Sven Wehrwein, administrateur d’AtriCure, Inc. (ATRC), a réalisé des opérations appariées le 22/08/2025. Il a levé 5 000 options d’achat non qualifiées au prix d’exercice de 19,95 $, acquérant ainsi 5 000 actions. Simultanément, il a vendu 5 000 actions ordinaires à 37,00 $ chacune. Après ces opérations, il détenait de manière bénéficiaire 34 374 actions et disposait d’options couvrant 35 000 actions exerçables jusqu’au 11/11/2026. Les options avaient été initialement attribuées le 11 novembre 2016 et acquièrent des droits selon le calendrier indiqué dans le dossier.

Sven Wehrwein, Direktor von AtriCure, Inc. (ATRC), führte am 22.08.2025 abgeglichene Transaktionen durch. Er übte 5.000 nicht qualifizierte Aktienoptionen zum Ausübungspreis von $19,95 aus und erwarb 5.000 Aktien. Gleichzeitig verkaufte er 5.000 Stammaktien zu $37,00 pro Aktie. Nach diesen Transaktionen hielt er wirtschaftlich 34.374 Aktien und verfügte über Optionen auf 35.000 Aktien, die bis zum 11.11.2026 ausübbar sind. Die Optionen wurden ursprünglich am 11. November 2016 gewährt und vesten gemäß dem im Bericht angegebenen Zeitplan.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEHRWEIN SVEN

(Last) (First) (Middle)
4877 EAST LAKE HARRIET PARKWAY

(Street)
MINNEAPOLIS MN 55419

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/22/2025 M 5,000 A $19.95 39,374 D
Common Stock 08/22/2025 S 5,000 D $37 34,374 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (right to buy) $19.95 08/22/2025 M 5,000 11/11/2017(1) 11/11/2026 Non-qualified Stock Option (right to buy) 5,000 $0 35,000 D
Explanation of Responses:
1. These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.
Remarks:
/s/ Sven Wehrwein 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did ATRC director Sven Wehrwein report on 08/22/2025?

He exercised 5,000 non-qualified stock options at $19.95 and sold 5,000 common shares at $37.00 on 08/22/2025.

How many ATRC shares does Sven Wehrwein beneficially own after the reported transactions?

Following the transactions he beneficially owns 34,374 shares according to the Form 4.

How many ATRC options does the reporting person still hold and when do they expire?

The Form 4 reports 35,000 exercisable options with an expiration date of 11/11/2026.

When were the options granted that were exercised?

The filing states these options were granted on November 11, 2016 and vest according to the schedule disclosed.

Were these transactions reported promptly under Section 16?

Yes, the Form 4 was signed and dated 08/26/2025, disclosing the 08/22/2025 transactions.
Atricure

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Latest SEC Filings

ATRC Stock Data

1.88B
47.96M
3.23%
100.57%
4.48%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MASON